FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Real-time Bid/Ask 05:31:17 26/06/2024 pm IST | ||
| 4.53 EUR / 4.63 EUR | +1.78% |
|
| Current month | -5.46% | ||
| 1 month | -21.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 26/24/26 | 4.5 | +7.14% |
| 24/24/24 | 4.2 | -6.67% |
| 21/24/21 | 4.5 | +3.93% |
| 20/24/20 | 4.33 | -6.68% |
| 19/24/19 | 4.64 | +2.88% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 01:18 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK7Z4X |
| ISIN | DE000JK7Z4X2 |
| Date issued | 26/04/2024 |
| Strike | 271.9 $ |
| Maturity | Unlimited |
| Parity | 10.45 : 1 |
| Emission price | 10.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.02 € |
|---|---|
| Lowest since issue | 3.54 € |
| Spread | 0.1 € |
| Spread % | 2.16% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
223.2
USD
Average target price
283.2
USD
Spread / Average Target
+26.87%
- Stock Market
- Certificates
- Certificat
